MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. LFST
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

LifeStance Health Group (LFST) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

LifeStance Health Group
NasdaqGS•Healthcare•Medical Care Facilities
$12.79-0.27(-0.02%)Pre-market
Market Cap
$4.91B
P/E
96.9x
P/S
3.1x
P/B
3.3x

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a multidisciplinary suite of mental health services, psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It also treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.

B

How this company scores

GoodMetricSide Score: 71/100

Strongest: Growth (24/25); weakest: Profitability (13/25).

Profitability13/25
Growth24/25
Balance Sheet & Red Flags18/25
Cash & Earnings Quality16/25
Strengths
Growing revenueRising free cash flowRising earningsLow leverage

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 96.9x5y range 96.9x – 285.6x
P/E 96.9x
P/S · 3.1x5y range 0.0x – 3.1x
P/S 3.1x · above its 17-quarter median

Currently above its 17-quarter median.

P/B · 3.3x5y range 0.0x – 3.3x
P/B 3.3x · above its 17-quarter median

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 4 quarters — monitor for earnings quality deterioration.

Price & Volume
Market Cap $4.91B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$1.58B
7Q
Q. Revenue
$435.35M
7Q
TTM EBITDA
$120.80M
7Q
TTM Op. Income
$78.43M
7Q
Q. Op. Income
$30.65M
4Q
TTM Net Income
$50.60M
7Q
Q. Net Income
$23.61M
4Q
EPS
N/A
Shares Out.
$383.52M
1%
$1.58B in TTM revenue grew 20.4% YoY, reaching $435.35M last quarter. TTM EBITDA of $120.80M and TTM operating income of $78.43M show growth is flowing through to the bottom line. TTM net income of $50.60M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin
9.6%
4Q
Op. Margin
7.0%
4Q
Net Margin
5.4%
4Q
Op. margin of 7.0% is up 7.9% YoY — cost efficiency is improving. Net margin at 5.4% Across the last 8 quarters, operating margin has risen for 4 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
96.9x
2Q
P/S Ratio
3.1x
104%
P/B Ratio
3.3x
145%
At 96.9x P/E, the stock trades above typical market levels — the market expects above-average growth. P/S of 3.1x and P/B of 3.3x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Across the last 3 quarters, P/E has fallen for 2 consecutive quarters — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$2.18B
2%
Cash
$225.94M
20%
Long-Term Debt
$258.99M
6Q
Book Value
$1.48B
2Q
D/E Ratio
0.2
5%
Debt/EBITDA
6.2
4Q
With $2.18B in assets and $258.99M in long-term debt, D/E is 0.2and book value is $1.48B — a conservative capital structure with a cushion to weather downturns. Over the past year, debt/equity is down 5% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$99.91M
55%
TTM Free Cash Flow
$173.91M
2Q
FCF Margin
11.0%
2Q
FCF / Net Income
3.4
2Q
TTM FCF of $173.91M on $99.91M in operating cash flow. The FCF / Net Income ratio of 3.4x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 2 consecutive quarters — an improving trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General

Currently above its 17-quarter median.